Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...

Researchers engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five ...

FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive prostate cancer (mCSPC), following results from the Phase 3 AMPLITUDE ...

GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...

An international PANORAMA study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on routine CT scans. Across 3,440 patients, AI achieved an AUROC of 0 ...

Preoperative radiation boosted antitumor immunity and treatment response in HR positive, HER2 negative breast cancer in the phase II P RAD trial presented at SABCS 2025. When combined with ...

The Phase 3 EV-304 KEYNOTE-B15 trial showed that perioperative enfortumab vedotin (PADCEV) plus pembrolizumab (Keytruda) significantly improved event-free survival and overall survival versus ...

Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab regimen increased objective response rates from 37% to 49%, tripled median ...

The FDA has approved T-DXd (Enhertu) plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer, the first new option in over a decade. In the Phase III ...

Presented at the 2025 SABCS annual meeting, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease recurrence or death by 30% in early-stage ER-positive ...

The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated NSCLC, enabling five-minute administration with fewer infusion reactions. In Phase III PALOMA-3, ...